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NON-COMPETITIVE PEAK DECAY ANALYSIS OF DRUGPROTEIN DISSOCIATION BY HIGH-PERFORMANCE AFFINITY
CHROMATOGRAPHY
Jianzhong Chen, John E. Schiel, and David S. Hage*
Chemistry Department, University of Nebraska, Lincoln, NE 68588-0304 USA

Abstract
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The peak decay method is an affinity chromatographic technique that has been used to examine
the dissociation of solutes from immobilized ligands in the presence of excess displacing agent.
However, it can be difficult to find a displacing agent that does not interfere with detection of the
eluting analyte. In this study, a non-competitive peak decay method was developed in which no
displacing agent was required for analyte elution. This method was evaluated for the study of
drug-protein interactions by using it along with high-performance affinity chromatography to
measure the dissociation rate constants for R- and S-warfarin from columns containing
immobilized human serum albumin (HSA). Several factors were considered in the optimization of
this method, including the amount of applied analyte, the column size, and the flow rate. The
dissociation rate constants for R- and S-warfarin from HSA were measured at several temperatures
by this approach, giving values of 0.56 (± 0.01) and 0.66 (± 0.01) s−1 at pH 7.4 and 37°C. These
results were in good agreement with previous values obtained by other methods. This approach is
not limited to warfarin and HSA but could be employed in studying additional drug-protein
interactions or other systems with weak-to-moderate binding.
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1 Introduction
Information on the kinetics of a biomolecular interaction is useful in the design of many
methods that employ biological ligands for chemical separations or analysis. Surface
plasmon resonance and other biosensor systems can be utilized to obtain such information
[1–3], but affinity chromatography can also be employed for this purpose. Kinetic methods
based on affinity chromatography include band-broadening measurements, peak profiling,
and split-peak analysis [4–6]. However, each of these techniques has limitations. Bandbroadening measurements work well for systems with relatively fast association and
dissociation kinetics; however, this technique requires careful control of the system and
precise measurement of peak variances at many flow rates [7–11]. Peak profiling is a
closely-related method that also requires careful peak variance measurements, but this
approach instead uses high flow rates to determine rate constants for an analyte on an
affinity column [6]. The split-peak method makes use of area measurements for non-bound

*

Correspondence: Professor David S. Hage, Department of Chemistry, University of Nebraska, Lincoln, NE 68588-0304 USA;
dhage@unlserve.unl.edu; Fax: +402-472-2744.

Chen et al.

Page 2

analyte fractions and is usually performed at high flow rates; this approach tends to give best
results for systems with strong binding and slow dissociation kinetics [12,13].
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The peak decay method is an attractive alternative to these other techniques when working
with biomolecular systems that have intermediate rates of dissociation [4,5,14]. In past work
with this approach, the release of an analyte from an immobilized ligand has been measured
under conditions in which analyte reassociation is made negligible by the presence of a high
concentration of a competing agent [4]. This analysis has been performed by first saturating
the immobilized ligand with the analyte and then quickly changing to a mobile phase that
has a high concentration of a competing agent, thus promoting release of the analyte through
mass action. For instance, the dissociation rate of fluorescent sugar analogs from
immobilized concanavalin A has been examined by this method when using a nonfluorescent sugar as a competing agent [14]. If this method is conducted under appropriate
flow rate and competing agent conditions, elution of the displaced analyte can be treated as a
first-order process that provides the dissociation rate constant for the release of analyte from
the immobilized ligand in the column [4,14].
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This report will examine the development of a non-competitive peak decay method that can
be performed with weak-to-moderate affinity systems and without the use of a displacing
agent. This approach will be tested by using it in high-performance affinity chromatography
(HPAC) to examine dissociation of the drug warfarin from columns that contain human
serum albumin (HSA). HSA is a 66.5 kDa plasma protein that binds to many drugs and
small organic compounds in blood. Warfarin is a chiral anticoagulant drug that is known to
bind to HSA at the warfarin-azapropazone site, or Sudlow site I [15,16]. The association
equilibrium constants for HSA with the R- and S-enantiomers of warfarin have been
determined to be in the range of 2.4–4.1 × 105 M−1 at pH 7.4 and 37°C [17–19]. Information
is also available on the rate constants for these interactions [9,20–25]. All of these properties
make this system a useful model for developing and evaluating a non-competitive peak
decay method for the study of drug-protein interactions. Several theoretical and practical
factors will be considered in the optimization of this method, including the effects of varying
the amount of applied analyte, the column size, and the flow rate of the mobile phase. The
results should provide useful guidelines in the extension of this approach to the study of
other drug-protein interactions or additional systems with weak-to-moderate binding.

2 Theory
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The reactions shown in Eqs. (1)–(2) have been used previously to describe analyte
interactions in an affinity column [4,14]. This model is based on a two-step process
involving (1) diffusion of the analyte into and out of the pores of the support and (2) analyte
adsorption-desorption with an immobilized ligand that is located on the surface of the
support.

(1)

(2)

In these reactions, Ae and Ap represent the analyte in the flowing mobile phase (or excluded
volume) and stagnant mobile phase (or pore volume) of the support, respectively. Mass
transport of the analyte between the flowing mobile phase and stagnant mobile phase is
J Sep Sci. Author manuscript; available in PMC 2009 November 5.
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described in Eq. (1) by the forward and reverse rate constants k1 and k−1. In Eq. (2), L refers
to the immobilized ligand and A−L represents the analyte-ligand complex, while ka and kd
are the association and dissociation rate constants for interactions of the analyte with the
ligand.
The peak decay method originally reported in Refs. [4] and [14] made use of an affinity
column that was first saturated with the analyte. This analyte was then dissociated in the
presence of an excess of competing agent. At a sufficiently high flow rate, it was proposed
that this dissociation could be described by the two-step process shown in Eqs. (3)–(4), in
which reassociation of the analyte with the ligand and mass transfer of analyte from the
flowing mobile phase to the stagnant mobile phase are considered to be negligible on the
time scale of the experiment [4,14].
(3)

(4)
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In this situation, the elution profile for the analyte is represented by Eq. (5),

(5)

where t is the time allowed for elution, mAe is the moles of analyte eluting at time t, and mA0
is the initial moles of bound analyte in the column. If kd is much smaller than k−1 (i.e., the
elution of analyte is limited by its rate of dissociation from the ligand), Eq. (5) reduces to
Eq. (6).

(6)
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Eq. (6) makes it possible to obtain the dissociation rate constant for this system by preparing
a plot of the natural logarithm of the elution profile versus time, or ln(dmAe/dt) vs. t, which
should have a slope equal to −kd [14]. This particular expression is written for a system in
which only one type of interaction and a single dissociation rate constant can be used to
describe the release of A from the immobilized ligand. If several types of interactions are
present (e.g., specific binding plus non-specific binding or multi-site interactions of A with
L), Eq. (6) can still be used but would now give a weighted kd value that depends on the
relative amount of analyte that is undergoing each type of dissociation process.
One problem with using a competing agent in the peak decay method is this agent may
create a significant change in background signal when it is applied, making it difficult to
measure the rate of analyte dissociation from the column. This problem was avoided in this
current study for weak-to-moderate affinity systems by using a non-competitive peak decay
method. This was accomplished by working under column size and flow rate conditions that
maximized the chance of washing a retained analyte from the column after the analyte had
dissociated from the ligand and exited the stagnant mobile phase. If this process occurs
quickly, only a negligible amount of analyte should be able to reenter the stagnant mobile
phase. When both the rates of analyte dissociation and reassociation are much slower than
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this rate of mass transfer (i.e., ka[L]≪ k−1 and kd≪k−1), Eq. (6) can again be used to
describe the rate of analyte release from the column. This makes it possible to use a plot of
the natural logarithm of the peak decay response to give the dissociation rate constant for the
release of the analyte from the ligand (kd). If the association equilibrium constant (Ka) for
the binding of the analyte to the ligand is also known, the association rate constant for the
analyte with the ligand can also be determined by using the relationship Ka = ka/kd.
As indicated earlier, one assumption made in Eq. (6) is that ka[L] ≪ k−1. This means that the
rate of reassociation of the analyte with the ligand is assumed to be negligible compared to
the rate of mass transfer of the analyte from the stagnant mobile phase to the flowing mobile
phase. The size of the pseudo-first order rate constant for reassociation (ka [L]) can be
adjusted by passing through the affinity column a solution with a known, moderate or high
concentration of analyte [A]. This concept can be illustrated by using the ideal case in which
a local equilibrium is reached between the analyte and ligand for a system with single-site
binding. Under these conditions, the amount of analyte that is bound to the ligand (mL,app)
can be related to the true binding capacity of the column (mL) through the following
relationship [4,26].

(7)
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In this system, the moles of free ligand sites that remain in the column can be calculated by
finding the difference between mL and mL,app. Using the fact that [L] =(mL− mL,app)/VM
gives Eq. (8), where VM is the column void volume.
(8)

Eq. (8) indicates that a small value for ka [L] (i.e., as needed for slow reassociation) can be
obtained if there is a reasonably high concentration of analyte that can bind to the column
and produce a low concentration of free ligand. Although Eqs. (7) and (8) were derived for a
system at local equilibrium, the same general factor(s) that lead to a small value for ka [L]
and slow reassociation will also pertain to a peak decay analysis in which analyte-ligand
binding has not yet achieved a local equilibrium.
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Caution also must be taken to avoid using too large of a concentration for the applied
analyte because the excess analyte in solution can make it difficult to later observe the decay
profile for retained analyte as it dissociates from the column. This concept can be
represented by the following relationship, as is again derived for a simple system in which a
local equilibrium is present between the analyte and ligand for a system with single site
binding.

(9)

This equation shows that an increase in analyte concentration will eventually cause the ratio
of the free analyte to bound analyte in the mobile phase ([A]/[A−L]) to increase. This will
make it difficult under such conditions to observe a decay curve due to the excess of free
analyte that is washing from the column. The same issue will be present in a system in
which the analyte and ligand have not yet reached a local equilibrium. Such a problem can
be reduced by decreasing [A], but too large of a decrease in [A] will create a situation in
J Sep Sci. Author manuscript; available in PMC 2009 November 5.
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which reassociation is likely to occur, as indicated by Eq. (8). Thus, both the rate of
reassociation and the amount of excess analyte in solution need to be considered when
selecting sample conditions for a non-competitive peak decay analysis.

3 Materials and methods
3.1 Reagents
The HSA (Cohn fraction V, approximately 99% pure, fatty acid free), racemic warfarin, and
reagents for the bicinchoninic acid (BCA) protein assay were from Sigma (St. Louis, MO,
USA). The Nucleosil Si-300 (5 or 7 µm particle size with 300 Å pores) was from P.J. Cobert
(St. Louis, MO, USA). The R- and S-warfarin were donated by Dupont Pharmaceuticals
(Wilmington, DE). All other chemicals and biochemicals were of the purest grades
available. All solutions were prepared in water obtained from a Nanopure water system
(Barnstead, Dubuque, IA, USA).
3.2 Apparatus
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The chromatographic system consisted of one CM300 isocratic pump (Milton Roy, Riviera
Beach, IL, USA) and one RF-535 fluorescence detector (Shimadzu, Kyoto, Japan). Samples
were injected using a Rheodyne PR700-100 injection valve (Cotati, CA, USA) or an
AS3000 autosampler from Thermoseparations (Schaumberg, IL, USA) with a 100 µl sample
loop. The elution profiles were collected using Labview software from National Instruments
(Austin, Texas, USA) and processed using spreadsheets written in Excel (Microsoft,
Redmond, WA). The columns were packed using a CM3200 pump from LDC Analytical
(Riviera Beach, FL, USA) and a modified Valco N60 six-port valve (Houston, TX, USA), as
reported previously [27]. The column and mobile phase temperatures were controlled using
an Isotemp 9100 circulating water bath (Fisher Scientific, Pittsburgh, PA).
3.3 Methods
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Two types of HPLC-grade silica (Nucleosil Si-300 with 5 or 7 µm particle size) were used
in this study. Diol-bonded silica was prepared from each of these starting supports according
to a previous procedure [28]. The diol content was determined by an iodometric capillary
electrophoresis assay [29] to be 212 (± 2) µmol/g for the 7 µm silica and 276 (± 2) µmol/g
for the 5 µm silica, where the numbers in parentheses represent a range of ± 1 S.D. HSA was
immobilized to these supports by the Schiff base method [26]. The protein content for the
final supports was 730 (± 10) nmol HSA/g silica for the 7 µm silica and 930 (± 20) nmol
HSA/g silica for the 5 µm silica, as determined in triplicate by a BCA assay [30] using HSA
as the standard and diol-bonded silica as the blank. Both the HSA and control supports
(containing no immobilized HSA) were packed at 3000 psi into 2.5 mm × 2.1 mm I.D.
columns using pH 7.4, 0.067 M potassium phosphate buffer as the packing solution. These
columns were stored in this pH 7.4 buffer at 4°C until use. From the known protein content
of the HSA support and reported activity for HSA that has been immobilized by the Schiff
base method [19,26], it was estimated that there were 1.50 nmol of warfarin binding sites in
the HSA column.
All mobile phases were filtered through a 0.45 µm cellulose acetate filter and degassed
under vacuum for 10 min prior to use. Warfarin was detected by using its fluorescence at an
excitation wavelength of 320 nm and an emission wavelength of 380 nm. The noncompetitive peak decay method was optimized and characterized using injections of racemic
warfarin in the presence of pH 7.0, 0.1 M potassium phosphate buffer and at 25°C on
columns packed with 5 µm or 7 µm silica particles. Later experiments examining the
dissociation of R- and S-warfarin from HSA at various temperatures were performed on a
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column packed with 5 µm silica and using pH 7.4, 0.067 M potassium phosphate buffer as
the mobile phase.
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The concentrations of warfarin applied to the HSA and control columns ranged from 0.1–30
µM (note: it has been shown in previous reports that warfarin has little or no measurable
non-specific binding to the types of supports that were used within these columns under
such conditions) [9,19]. The flow rates used in this study ranged from 0.1 to 5 ml/min. The
back pressure across each column was less than 2500 psi under these conditions. The
chromatographic data were collected at a rate of 4 points/s. After collection, these results
were used to prepare a plot of the natural logarithm of response versus time. The slope of
this response was then used to obtain the dissociation rate constant for the analyte-ligand
interaction, as shown earlier in Eq. (6).

4 Results and discussion
4.1 General peak decay results
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Figure 1 shows typical decay curves and logarithmic decay profiles that were obtained for
injections of racemic warfarin on a 2.5 mm × 2.1 mm I.D. HSA column and control column
of identical size. In this example, a 100 µl sample of 10 µM warfarin was applied at 25°C
and a flow rate of 4 ml/min. As the sample first entered these columns, some of the applied
warfarin was bound by the HSA. The use of a relatively large amount of warfarin in the
sample allowed the immobilized HSA to become partially saturated during this step. As the
non-bound warfarin was washed from the column, some of the warfarin that had been bound
to HSA began to slowly dissociate and was carried off the column to the detector.
According to Eq. (6), a plot of the natural logarithm for the detector response versus time
should give a straight line for the dissociation-limited release of analyte from the
immobilized ligand. After excess warfarin had been washed from the column, a linear
change in the natural logarithm of the response was indeed observed, as shown in Figure
1(b). The control column also gave a relatively linear relationship. This latter response was
used to help minimize the effects of analyte washing and mass transfer during the peak
decay studies. It can be seen in Figure 1 that excess analyte was washed from the column in
a relatively short period of time (i.e., less than 10 s in this specific example). However, the
retained analyte was released over longer periods of time. To avoid overlap between the
response for the excess analyte and dissociating analyte, all further measurements of the
peak decay slopes were performed at times greater than those observed for the elution of
excess analyte from the control column (e.g., times greater than 10 s in Figure 1).
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4.2 Column size & plate height considerations
The peak decay method developed in this report generally requires the use of a small column
to minimize reassociation of the analyte after it dissociates from the column. Ideally, the
column should contain less than one theoretical plates for such work (i.e., less than one
effective equilibration step between the analyte and immobilized protein used as the
stationary phase). In earlier studies with an HSA support similar to those used in this report,
it was estimated that the plate heights for R- and S-warfarin on a 4.5 cm × 4.1 mm I.D.
column were in the range of 0.03–0.50 cm when working at 4–45°C and a linear velocity of
0.005–0.04 cm/s [8]. For the 2.5 mm × 2.1 mm I.D. HSA column employed in this current
report, this would correspond to 0.5–8 theoretical plates at a flow rate of 0.01–0.08 ml/min.
Much higher flow rates (i.e., up to 4 ml/min) were used with this small column in the peak
decay measurements conducted in this current report. These conditions provided an even
lower number of theoretical plates and helped to minimize analyte reassociation with HSA
on the time scale of the experiment.

J Sep Sci. Author manuscript; available in PMC 2009 November 5.
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A second estimate of the number of theoretical plates that would be expected in a 2.5 mm ×
2.1 mm I.D. HSA column was made by using chromatographic band-broadening theory. To
do this, the total plate height for the column (Htot) was calculated by finding the sum of
contributions due to mobile phase mass transfer (Hm), longitudinal diffusion (Hl), stagnant
mobile phase mass transfer (Hsm), and stationary phase mass transfer (Hk), as described by
the following relationships [4,31].

(10)

(11)

(12)
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(13)

In Eqs. (10)–(13), u is the linear velocity, k’ is the analyte’s retention factor, Vp is the
column pore volume, dp is the particle diameter of the support, γ is the obstruction or
tortuosity factor, and Dm is the diffusion coefficient for the analyte in the mobile phase. All
other terms are as defined previously. The plate height contribution due to extra-column
band broadening (Hec) was also considered in these calculations by using equations given in
Ref. [33].
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To estimate the size of these plate height terms, the retention factor for warfarin was
calculated from the binding capacity of the column (mL) and the association equilibrium
constant for the analyte with the immobilized ligand (Ka) by using the relationship k’ = Ka
mL/VM (note: a calculated value for k’ was used due to the low number of theoretical plates
for the HSA column used in this study, which made direct measurements of the retention
factor impractical). An average value for kd was obtained by using previous estimates of this
parameter for warfarin with immobilized HSA (i.e., 0.14–0.40 s−1 at 25°C for R- and Swarfarin) [9] and the values for kd that were obtained later in this report (i.e., 0.34–0.37 s−1
at 25°C for racemic warfarin). The mass transfer constant k−1 was calculated for warfarin
according to the following formula [4],
(14)

where Dm for warfarin was estimated to be 5 × 10−6 cm2/s [32], γ was assigned a value of
0.5 (a typical result for a small analyte), and dp was set equal to a particle diameter of 7 µm.
This gave an estimated value for k−1 of 306 s−1.
Table 1 shows the results calculated for the various plate height terms under the conditions
employed in this study to examine the dissociation rate of warfarin from HSA at 25°C using
7 µm silica (Note: values for HL are not shown since these were all less than 10−4 cm and
were not significant compared to other plate height terms). As can be seen from these
J Sep Sci. Author manuscript; available in PMC 2009 November 5.
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results, the total plate height estimated for this system would be expected to increase as the
flow rate was increased, resulting in less than one theoretical plate at the upper end of the
flow rate range considered in this study. This confirmed that such flow rates were adequate
for peak decay experiments by minimizing warfarin reassociation after it had been released
from a 2.5 mm × 2.1 mm I.D. HSA column. The same general result was obtained when
these plate height calculations were made for warfarin and HSA at the other temperatures
that were examined (i.e., 4 and 37°C, as based on data from this report and Refs. [9,19])
4.3 Effects of flow rate and analyte concentration
As shown in Table 1 for a 2.5 mm × 2.1 mm I.D. HSA column, the plate height contribution
due to analyte-ligand dissociation (i.e., the stationary phase mass transfer term, Hk) would
be expected to increase as the flow rate increases. Furthermore, as the flow rate increases to
about 3.0 ml/min, this plate height term accounts for more than 80% of the total plate height.
This indicated that work under such flow rate conditions would not only help prevent
analyte reassociation but would also increase the relative importance of analyte dissociation
versus mass transfer in determining the slope of the peak decay response. This effect is
illustrated by the leveling that was found to occur in the absolute value of this slope for
racemic warfarin as the flow rate is increased on a 2.5 mm × 2.1 mm I.D. HSA column, as
shown in Figure 2.

NIH-PA Author Manuscript

The effect of changing the analyte concentration on the behavior of the peak decay curves
was also examined. This was considered by using 100 µl samples of 1–10 µM racemic
warfarin applied at various flow rates to a 2.5 mm × 2.1 mm I.D. HSA column and control
column. A summary of the results that were obtained are given in Table 2. The peak
retention times seen for the 1 µM sample of racemic warfarin were longer than those
observed for the 10 µM warfarin sample at all flow rates. This was expected because under
the given experimental conditions the relatively large sample concentration partially
saturated the column, giving rise to non-linear elution conditions and weaker retention for
the analyte. Another difference between the 1 and 10 µM warfarin results was in the
dependence of their peak decay slopes on the flow rate. For the 1 µM warfarin sample, the
slope measured for the HSA column continued to change as the flow rate increased from 0.1
to 4 ml/min; however, an essentially constant slope was obtained for the 10 µM sample at
flow rates higher than 3 ml/min. This supported the conclusion made earlier that the use of
faster flow rates help minimize the effects of mass transfer and reassociation on peak decay
results [14]. As a result, the fact that the larger warfarin concentration gave a smaller flow
rate effect was not surprising because the higher degree of column saturation with this
sample made reassociation less likely to occur.
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The 100 µl sample volume used in this study was much larger than the void volume of the
HSA and control columns, which had a value of approximately 8.7 µl. This allowed for the
injected analyte to have more time to bind the immobilized ligand. This greater extent of
initial binding helped to lower the term ka [L] during the peak decay analysis when the
retained analyte later began to dissociate from the column (see Theory). From the known
protein content and volume and estimated binding capacity of the HSA column (i.e., 1.5
nmol warfarin), the effective concentration of active ligand in this column was determined
to be 172 µM. The total amount of analyte applied in 100 µl of the 1 and 10 µM warfarin
samples was 0.1–1.0 nmol. This meant that the moles of analyte in the highest concentration
sample represented approximately two-thirds of the estimated column binding capacity.
Figure 3 shows how the value of ka [L] (i.e., as related to the effective rate of analyte
association) would vary with the mobile phase concentration of analyte [A] if the HSA
column had reached a local equilibrium with the sample during injection; this plot also
shows how the relative amount of analyte in solution versus analyte bound to the ligand (as
J Sep Sci. Author manuscript; available in PMC 2009 November 5.
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given by the ratio [A]/[A−L]) would vary under these conditions. To obtain accurate rate
constants measurements, it is desirable to have a large fraction of bound analyte (i.e., low
[A]/[A−L]) while also minimizing analyte reassociation (i.e., low ka [L]). These conditions
maximize the amount of analyte for which dissociation is measured and reduce multiple
interactions of the analyte with the stationary phase. It can be seen from Figure 3 that low
sample concentrations would be expected to result in a large amount of bound versus free
analyte at equilibrium (i.e., a small ratio for [A]/[A−L]). However, these conditions also
gave relatively large values for ka [L] (approximately 27 s−1 below 0.1 µM), which was
undesirable since it would create more reassociation. Sample concentrations up to 30 µM
should give a decrease in ka [L] (5.7 s−1 at 10 µM or 2.3 at 30 µM) without significantly
decreasing the relative amount of free versus bound analyte (i.e., increasing [A]/[A−L] to
only 0.06 at 10 µM or 0.15 at 30 µM). Higher sample concentrations would lead to a large
increase in the relative amount of free warfarin and a higher background signal. These
results agree with the general observation made throughout this report that 10–30 µM
warfarin samples gave better decay curves than 1 µM samples under the stated experimental
conditions and provided less background interference than higher concentration samples.
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It was further possible to compare the expected values of ka[L]/k−1 for these two types of
samples (i.e., 1 µM and 10 µM warfarin). This was accomplished by using previous
estimates made for k−1 and [L] and an average association rate constant of 1.0 ×105 M−1s−1
for warfarin with HSA at 25°C [9]. This calculation gave values for ka[L]/k−1 of 0.03 and
0.08 (or 3% and 8%) for the 10 µM and 1 µM warfarin samples, respectively. These ratios
provided some information concerning the validity of the assumption that analyte
reassociation was not significant during the peak decay studies. The small value of ka[L]
indicated that analyte-ligand association in this case should be slow relative to analyte
diffusion out of the pores. The lower value of ka[L]/k−1 obtained for the 10 µM sample
indicated that the assumption that analyte reassociation was not significant was slightly
better for this sample than it was for the 1 µM sample.
4.4 Comparison of peak decay results for HSA columns with different size supports
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The last item considered during the optimization of the peak decay method was the effect of
varying the particle size and efficiency of the support within the column. This was of
interest because an efficient column with fast mass transfer would allow dissociation rate
constants to be more easily measured. However, efficient columns would also result in small
plate heights, which would allow for greater reassociation of analyte during its release from
the column. To study this further, two series of columns were prepared with identical
lengths but different sized support particles (i.e., 300 Å porous supports with a mean
diameter of 5 or 7 µm). Injections of 100 µl 10–30 µM warfarin were then made to each
column at 0.5–5.0 ml/min. The larger concentrations of warfarin used in this experiment
versus those employed in the earlier studies was due to the greater surface area of the
supports in this particular experiment and the larger amount of immobilized HSA that was
present within these columns.
Figure 4 shows some typical chromatograms that were obtained on the control and HSA
columns containing 7 µm silica as the flow rate was varied. Similar results were obtained for
columns containing 5 µm silica (data not shown). For the HSA column containing 7 µm
silica , the slope approached a constant value in the logarithmic plots as the flow rate
exceeded 3.0 ml/min (see Figure 2). For the HSA column containing 5 µm silica, the slope
also approached a plateau as the flow rate increased but the leveling of this slope now
occurred more gradually and the plateau was reached at slightly higher flow rates (i.e., 3.5–
4.0 ml/min). These differences were expected due to the better efficiency of the columns
containing 5 µm vs. 7 µm silica. However, both types of columns gave comparable slopes
and values for kd when using data from their plateau regions (i.e., kd = 0.34–0.37 s−1). This
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result indicated that mass transfer effects were not a problem with either type of column
when peak decay data was obtained at higher flow rates and in the plateau region of plots
like those in Figure 2.
4.5 Determination of dissociation rates for R- and S-warfarin from HSA
The final series of experiments used the non-competitive peak decay method to study the
dissociation of warfarin from immobilized HSA at pH 7.4. These experiments were carried
out in the presence of pH 7.4, 0.067 M potassium phosphate buffer using a 100 µL sample
that contained 20 µM of R- or S-warfarin. A 2.5 mm × 2.1 mm I.D. HSA column containing
5 µm silica was used in this part of the study and the temperature of this column was held at
either 4°C or 37°C. To avoid thermal mismatches during these experiments, the samples and
mobile phase were kept at the same temperature as the column by means of a circulating
water bath. In addition, all samples and mobile phase solutions were passed through a
serpentine coil of tubing held at the same temperature as the column prior to contact with
immobilized HSA. Measurements of the mobile phase and column temperatures with this
system gave a difference of less than 0.2°C even when working at flow rates up to 5.0 ml/
min. Identical studies were performed with the control columns. Some typical peak decay
profiles that were obtained are shown in Figure 5.
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At 4°C, the slopes obtained for peak decay plots generated at 4.0–5.0 ml/min were quite
close for the two enantiomers of warfarin. The plateau region of these plots gave
dissociation rate constants of 0.39 (± 0.01) and 0.44 (± 0.01) s−1 for R- and S-warfarin,
respectively. At 37°C, the plateaus of the peak decay plots were less pronounced, as might
be caused by faster mass transfer and reassociation, but the results obtained at the highest
flow rates were still used to provide estimates of the dissociation rate constants for the
warfarin-HSA system. Under these conditions, the dissociation rate constants were
determined to have apparent value of 0.56 (± 0.01) and 0.66 (± 0.01) s−1 for R- and Swarfarin, respectively.
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The rate constants measured in this work were close to the average value of 0.7 s−1 that has
been determined for racemic warfarin with solution-phase HSA at 6°C by stopped flow
analysis [20]. These results also agreed with previous dissociation rate constants that have
been measured for immobilized HSA, where values of 0.1–2 s−1 at 4–37°C have been
determined using surface plasmon resonance [34] and values of 0.06–0.56 s−1 have been
reported at 4–37°C using chromatographic band-broadening studies [9]. Thus, there
appeared to be good agreement between the results of this current work and previous values
in the literature. This comparison indicated that the non-competitive peak decay method
developed in this study could be used as an effective tool in determining the dissociation rate
constants for the warfarin-HSA system.

5 Concluding remarks
In this study a modified non-competitive peak decay method was developed and optimized
for the study of drug-protein dissociation in weak-to-moderate affinity systems. This
approach was tested by used it to examine the dissociation of warfarin from HSA. Several
parameters were considered in the development of this method, including the effects of
changing the column size, analyte concentration, sample volume, flow rate, and particle size
of the support material. Dissociation rate constants were obtained for R- and S-warfarin
during their release from HSA at pH 7.4 and 4°C or 37°C, as well as the average
dissociation rate constant for racemic warfarin from HSA at pH 7.0. These results are
summarized in Table 3. The results obtained by this method were similar to those
determined previously by other methods for both soluble and immobilized HSA [9,20,34].
The agreement of these results indicated that this approach could be used to successfully
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estimate drug-protein dissociation rates, especially in work with weak-to-moderate affinity
proteins like HSA.
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This non-competitive peak decay method has several possible advantages in the study of
drug-protein kinetics and other systems with relatively fast association/dissociation kinetics.
For instance, previous peak decay theory was revised in this work to consider analyte
reassociation, thereby eliminating the need for a competing agent and its associated
experimental complications [4,14]. In comparison to earlier studies using band-broadening
measurements, this new approach does not require the estimation or measurement of plate
heights, which can be a tedious process [4]. Because linear elution conditions are not
required, this method can also use higher analyte concentrations than band-broadening
measurements. In addition, this new technique does not require a change in flow rate or
mobile phase between the sample application and elution steps, as is needed in previous
peak decay work, which avoids changes in the background response due to flow rate and
pressure changes [4,14]. These features should make this approach useful in studying the
kinetics of other drugs with HSA or in the analysis of other solute-ligand systems with
similar equilibrium and rate constants. In addition, the ability of this method to work with
small columns and at high flow rates should make it appealing as a method for the highthroughput screening of drug candidates for their interactions with HSA and other proteins.
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Abbreviations
HPAC

high-performance affinity chromatography

HSA

human serum albumin

Nomenclature
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A

Analyte or solute applied to the column

dp

Packing material particle diameter

Dm

Diffusion coefficient of analyte in the mobile phase

[A]

Analyte concentration in the mobile phase

Ae

Analyte outside of the pores of the packing material

Ap

Analyte inside the pores of the packing material

A−L

Complex of analyte and immobilized ligand

Hk

Plate height due to stationary phase mass transfer

Hsm

Plate height due to stagnant mobile phase mass transfer

Hm

Plate height due to mobile phase mass transfer

Hl

Plate height due to longitudinal diffusion

Hec

Plate height due to extracolumn band-broadening

k’

Retention factor

k1

Diffusion rate constant of analyte from outside of the pore to inside

k−1

Diffusion rate constant of analyte from inside of the pore to outside

ka

Association rate constant
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kd

Dissociation rate constant

Ka

Association equilibrium constant

L

Immobilized ligand

mA0

Initial number of moles of adsorbed analyte

mAe

Number of moles of analyte eluted at time t

mL

Number of moles of active ligand in the column

mL,app

Apparent number of moles of analyte required to saturate the column

u

Linear velocity

VM

Void volume

Vp

Pore volume

γ

Tortuosity factor
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Figure 1.

Comparison of the (a) response and (b) logarithmic response profile for a 100 µl injection of
10 µM racemic warfarin onto a 2.5 mm × 2.1 mm I.D. control column or HSA column that
was prepared using Nucleosil 300-7 silica. These chromatograms were obtained at 25°C and
4 ml/min using pH 7.0, 0.10 M potassium phosphate buffer as the mobile phase.
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Figure 2.

Absolute values of the slopes measured at various flow rates from the logarithmic decay
profiles obtained on a 2.5 mm × 2.1 mm I.D. control column (■) or HSA column (◆)
containing 7 µm silica particles. The injections consisted of 100 µl of 10 µM racemic
warfarin made at 25°C and using pH 7.0, 0.10 M potassium phosphate buffer as the mobile
phase.
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Figure 3.

Theoretical plots showing the values expected for ka [L] (◆) and [A]/[A−L] (■) as a
function of log[A] if a local equilibrium is established between a warfarin sample and
immobilized HSA column. These results were calculated using Eqs. (8) and (9) along with
an average association equilibrium constant for racemic warfarin with HSA of 3.0 × 105
M−1 at 25°C, an association rate constant of 1.0 × 105 M−1 s−1 and a total effective
concentration of 172 µM for warfarin binding sites in the HSA column.
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Figure 4.

(a) Original chromatograms and (b) logarithmic peak profiles for 100 µl injections of 10 µM
racemic warfarin applied to a 2.5 mm × 2.1 mm I.D. HSA column or control column
containing 7 µm silica particles. The flow rates used in these experiments (from left-to-right)
were 4.0, 3.5, 3.0, 2.5, and 2.0 ml/min. The mobile phase was pH 7.0, 0.10 M potassium
phosphate buffer and the temperature was 25°C.
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Figure 5.

Representative decay profiles for R-warfarin at (a) 4°C and (b) 37°C. The chromatograms
represent elution at flow rates of (left to right) 5.0, 4.5, 4, 3.5, and 3.0 mL/min and were
obtained using a 100 µL sample containing 20 µM of R- or S-warfarin injected onto 2.5 mm
× 2.1 mm I.D. columns packed with 5 µm silica.
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(cm)

0.0006

0.0031

0.0062

0.0092

0.0123

0.0154

0.0185

0.0215

0.0246

(ml/min)

0.1

0.5

1

1.5

2

2.5

3

3.5

4

0.2095

0.1833

0.1571

0.1309

0.1047

0.0785

0.0524

0.0262

0.0052

(cm)

Hk

0.0035

0.0035

0.0035

0.0035

0.0035

0.0035

0.0035

0.0035

0.0035

(cm)

Hm

0.0145

0.0126

0.0133

0.0125

0.0183

0.0172

0.0189

0.0205

0.0229

(cm)

Hi

0.0009

0.0007

0.0007

0.0006

0.0007

0.0006

0.0005

0.0004

0.0004

(cm)

Hec

0.2530

0.2217

0.1931

0.1629

0.1396

0.1091

0.0814

0.0537

0.0326

(cm)

Htot

0.8279

0.8266

0.8135

0.8038

0.7503

0.7201

0.6431

0.4878

0.1605

Hk/Htot

0.9881

1.1275

1.2946

1.5350

1.7910

2.2919

3.0700

4.6574

7.6606

n

calculation.

where L is a column length of 2.5 mm in this particular example. An average value for racemic warfarin of 0.35 s−1 was used for kd and a value of 3.0 × 105 M−1 was used for Ka in this particular

The equations and methods used to determine the individual plate terms in this table are summarized in the text. The number of theoretical plates (n) was calculated by using the relationship n = L/Htot,

a

Hsm

Flow rate

Predicted plate height terms for racemic warfarin applied to a 2.5 mm × 2.1 mm I.D. HSA column at 25°C and various flow ratesa
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17.8

14.2

12.0

9.9

9.1

8.0

1.5

2.0

2.5

3.0

3.5

4.0

16.3
11.9
9.4
8.2
7.3
6.7
6.0

−0.150 (± 0.007)
−0.162 (± 0.007)
−0.190 (± 0.006)
−0.212 (± 0.014)
−0.236 (± 0.022)
−0.248 (± 0.019)

29.2

−0.094 (± 0.006)

−0.061 (± 0.002)

−0.344 (± 0.007)

−0.347 (± 0.007)

−0.344 (± 0.003)

−0.250 (± 0.006)

−0.229 (± 0.009)

−0.196 (± 0.002)

−0.147 (± 0.012)

−0.086 (± 0.005)

4.2

4.5

4.8

5.1

6.2

7.5

10.0

17.1

82.4

tp (s)

−1.226 (± 0.013)

−0.981 (± 0.015)

−0.915 (± 0.013)

−0.855 (± 0.006)

−0.666 (± 0.007)

−0.551 (± 0.009)

−0.443 (± 0.012)

−0.182 (± 0.002)

−0.051 (± 0.001)

Slope (s−1)

10 µM Warfarin
on control column

The values in parentheses represent a range of ± 1 S.D. All experiments in this table were performed using a 100 µl sample volume.

a

25.7

48.6

1.0

0.5

139.6

−0.015 (± 0.001)

−0.020 (± 0.001)

Slope (s−1)

tp (s)

Slope (s−1)

231.3

tp (s)

10 µM Warfarin
on HSA column

1 µM Warfarin
on HSA column

0.1

Flow rate
(ml/min)

Elution time of peak maximum (tp) and slopes of peak decay curves for racemic warfarin on the HSA column and control columns at 25°C and various
flow ratesa
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Table 3

Summary of dissociation rate constants determined by the peak decay method for warfarin from HSA
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Dissociation rate constant, kd (s−1)a
Temperature

R-Warfarin

S-Warfarin

Racemic warfarin

4°C

0.39 (± 0.01)

0.44 (± 0.01)

---

37°C

0.56 (± 0.01)

0.66 (± 0.01)

---

25°C

---

---

0.35 (± 0.02)b

a

The values for the individual enantiomers of warfarin were measured in pH 7.4, 0.067 M potassium phosphate buffer, while the value for the
racemic mixture was measured in pH 7.0, 0.10 M potassium phosphate buffer. The values in parentheses represent a range of ± 1 S.D.
Individual estimates for kd ranged from 0.34 s−1 to 0.37 s−1 for the various columns and analysis conditions used in this study.

b
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